Alto Pharmacy Exit Candidate

πŸ¦„
Employees 500+
Primary contact

🏦 Potential exit path: SPAC, IPO, M&A
Alto is on a mission to transform a $500 billion industry by reinventing what a pharmacy can do. It is a digital pharmacy that provides customers with access to medication by scheduling delivery to their home or office the same day, seven days a week. People can also see medication price comparisons, manage their medications, and connect directly with a pharmacist to help them stay on track. Providers also use Alto's technology to streamline administrative workflows, like benefits investigation and insurance authorizations.
πŸ¦„
Employees 500+
Primary contact

Funding πŸ’°

Total πŸ¦„ $612.4M
Last round πŸ”— $200M
Series E
January 27, 2022.
Select investors SoftBank Vision Fund, Greenoaks Capital, Zola Global, Olive Tree Capital, Jackson Square Ventures, Nimble Ventures, Esas Ventures

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • Alto's service is already making a big impact, resulting in 40% better adherence than the industry average while bringing prescription savings to patients (41%+).
  • As of January 2020, Alto is available in 12 markets across the United States, with its revenues growing to over $700 million annual run rate - up more than 100% in the last 12 months. πŸ”—
  • Alto has consistently earned a Net Promoter Score of 86, which is on par with top brands like Tesla and Apple - compared to negative five for the leading retail chain pharmacy. πŸ”—
  • "Alto's growth is a testament to their focus on improving the patient experience. By reimagining the core pharmacy software, we believe Alto has improved the quality of care and health outcomes for over 50,000 patients in California." - Neil Shah at Greenoaks Capital πŸ”—
  • In August 2021, the company got an experienced CEO - Kevin Burns, who was previously CEO at JUUL Labs and before that, President and COO at Chobani. πŸ”—
Last update: February 2, 2022